Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT ID: NCT04152941
Last Updated: 2023-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
130 participants
OBSERVATIONAL
2018-10-11
2020-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
NCT03402841
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
NCT04532645
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
NCT01650376
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
NCT01081951
Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
NCT02383251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olaparib
Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
* Patients can be either alive or deceased at the time of medical record abstraction
* Patients should not have any objection that anonymized data will be collected and subjected to automated processing.
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thibault de La Motte Rouge, Dr
Role: PRINCIPAL_INVESTIGATOR
Centre Eugène Marquis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICO Paul Papin
Angers, , France
Institut Sainte-Catherine
Avignon, , France
CHRU Jean Minjoz
Besançon, , France
Clinique Tivoli
Bordeaux, , France
Institut Bergonié
Bordeaux, , France
Clinique Pasteur
Brest, , France
Hôpital Morvan - Centre Hospitalier Universitaire
Brest, , France
Centre Jean Perrin
Clermont-Ferrand, , France
Centre Georges François Leclerc
Dijon, , France
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, , France
Institut Hospitalier Franco-Britannique
Levallois-Perret, , France
Centre Léon Bérard
Lyon, , France
ICM Val d'Aurelle
Montpellier, , France
ORACLE - Centre d'Oncologie de Gentilly
Nancy, , France
Hôpital Privé du Confluent S.A.S.
Nantes, , France
Centre Antoine Lacassagne
Nice, , France
Centre Hospitalier Régional d'Orléans
Orléans, , France
Hôpital Saint-Louis
Paris, , France
Hôpital Cochin
Paris, , France
Institut du Cancer Courlancy Reims
Reims, , France
Centre Eugène Marquis
Rennes, , France
Centre Hospitalier de Saint-Brieuc
Saint-Brieuc, , France
ICO Centre René Gauducheau
Saint-Herblain, , France
Clinique Mutualiste de l'Estuaire, Cité Sanitaire
Saint-Nazaire, , France
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, , France
Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
ICL Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, , France
Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GINECO-OV-237
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.